Impact of BPC-157 on Recovery Following Rotator Cuff Repair Surgery
Impact of BPC-157 on Recovery From Rotator Cuff Repair Surgery
This study is a randomized, double-blind, placebo-controlled pilot trial investigating the effects of BPC-157 on tendon healing and functional recovery following arthroscopic rotator cuff repair (aRCR). BPC-157 is a synthetic peptide that has demonstrated promising regenerative and anti-inflammatory effects in preclinical animal models of musculoskeletal injury, but it has not yet been studied in formal human clinical trials.
Twenty patients undergoing aRCR will be enrolled and randomly assigned to receive either BPC-157 or a saline placebo. Participants will self-administer subcutaneous injections daily for 90 days following surgery. All other aspects of care will follow the standard postoperative rehabilitation protocol.
The study will assess tendon healing using postoperative MRI, patient-reported outcome measures (PROMs), range of motion (ROM), and muscle strength via handheld dynamometry. Blood samples will also be collected to evaluate biomarkers associated with collagen turnover and inflammation.
The goal of this pilot study is to evaluate the safety, feasibility, and preliminary efficacy of BPC-157 in promoting tendon healing and improving functional outcomes after rotator cuff repair. Results will inform the design of a future larger-scale clinical trial.
調査の概要
研究の種類
入学 (推定)
段階
- フェーズ 1
連絡先と場所
研究場所
-
-
Arkansas
-
Little Rock、Arkansas、アメリカ、72205
- University of Arkansas for Medical Sciences Medical Center
-
コンタクト:
- Shiloah Kviatkovsky
- 電話番号:619-677-0792
- メール:skviatkovsky@uams.edu
-
主任研究者:
- Shiloah Kviatkovsky, P.h.D.
-
副調査官:
- Ryan Hill, M.D.
-
-
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
説明
Inclusion Criteria:
- Males and Females, 18 years old or older
- Body mass index of 20.0 to 34.9 kg/m2
- Pre-operative MRI demonstrating a full thickness tear of the posterosuperior rotator cuff less than 2.5 cm in anteroposterior dimension
- Scheduled for an aRCR at UAMS with Dr. Ryan Hill, Dr. Paul Inclan, or Dr. Justin Rabinowitz
- COVID-19 negative and/or asymptomatic
Exclusion Criteria:
- Previous RCR
- Pregnant or breastfeeding status
- Current drug and alcohol abuse · History of platelet-rich plasma injection, other platelet-based product or biologic injection in the past 12 months in the ipsilateral shoulder
- Lack of decisional capacity
- Having undergone hormone replacement therapy in the last 12 months
- Having undergone testosterone replacement therapy in the last 12 months
- Active diagnosis of blood borne infectious disease
- Diabetic
- Documented history or diagnosis of autoimmune disease
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:BPC-157 Group
Participants in this arm will receive BPC-157.
BPC-157 will be self-administered via subcutaneous injection once daily for 90 days following arthroscopic rotator cuff repair.
All participants will follow the standard postoperative rehabilitation protocol in addition to the study intervention.
|
BPC-157 is a synthetic pentadecapeptide derived from human gastric juice.
It has demonstrated pro-angiogenic, cytoprotective, and tissue-regenerative effects in multiple preclinical models of musculoskeletal injury, including tendon and ligament healing.
Although widely discussed in experimental and anecdotal contexts, BPC-157 has not undergone formal human clinical trials and remains an investigational compound not approved by the FDA.
This study is designed to explore its potential role in promoting tendon regeneration and functional recovery in a postoperative orthopaedic setting.
|
|
偽コンパレータ:Sham
Participants in this arm will receive normal saline.
Normal saline will be self-administered via subcutaneous injection once daily for 90 days following arthroscopic rotator cuff repair.
All participants will follow the standard postoperative rehabilitation protocol in addition to the study intervention.
|
Participants in this group will not receive any active treatment or placebo injections.
This sham group serves as a no-treatment control to evaluate the natural course of postoperative recovery following arthroscopic rotator cuff repair without investigational intervention.
Participants will continue to receive standard postoperative care and rehabilitation in accordance with institutional protocols.
This group is included to help differentiate the effects of BPC-157 from both placebo and routine recovery.
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Shoulder Strength
時間枠:Baseline, 12 weeks, and 5 months post operatively
|
Isometric shoulder abduction strength will be assessed using a handheld dynamometer.
Strength measurements will focus on shoulder abduction and external rotation at 0° abduction.
Three trials will be recorded, and the average peak force will be used as the outcome value.
Testing will be performed by a blinded evaluator using a standardized protocol.
|
Baseline, 12 weeks, and 5 months post operatively
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。